Clover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates

Bulletin Express03-30

Clover Biopharmaceuticals (Clover) has concluded participant enrollment for its Australian Phase 2 clinical study investigating two protein-based respiratory combination vaccine candidates—SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3).

\n\nKey trial parameters • Design: Randomized, observer-blinded, multi-center study. • Population: 420 older adults aged 60-85 years. • Intervention arms: SCB-1022, SCB-1033, and placebo. • Objectives: Assessment of safety, reactogenicity, and immunogenicity. • Technology platform: Prefusion-stabilized F (PreF)-Trimer antigens leveraging Clover’s Trimer-Tag platform. • Timeline: Initial read-outs are targeted for the third quarter of 2026.

\n\nThe Board advises shareholders and prospective investors to exercise caution when dealing in Clover’s shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175306947?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-30 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175306947","market":"hk","top_or_hot":-1,"title":"Clover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates","media":"Bulletin Express","content":"<p>Clover Biopharmaceuticals (Clover) has concluded participant enrollment for its Australian Phase 2 clinical study investigating two protein-based respiratory combination vaccine candidates—SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3).</p>\n<p>\\n\\nKey trial parameters  \n• Design: Randomized, observer-blinded, multi-center study.  \n• Population: 420 older adults aged 60-85 years.  \n• Intervention arms: SCB-1022, SCB-1033, and placebo.  \n• Objectives: Assessment of safety, reactogenicity, and immunogenicity.  \n• Technology platform: Prefusion-stabilized F (PreF)-Trimer antigens leveraging Clover’s Trimer-Tag platform.  \n• Timeline: Initial read-outs are targeted for the third quarter of 2026.</p>\n<p>\\n\\nThe Board advises shareholders and prospective investors to exercise caution when dealing in Clover’s shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Clover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClover Completes Enrollment of 420 Participants in Australian Phase 2 Trial for RSV-hMPV ± PIV3 Vaccine Candidates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-30 06:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Clover Biopharmaceuticals (Clover) has concluded participant enrollment for its Australian Phase 2 clinical study investigating two protein-based respiratory combination vaccine candidates—SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3).</p>\n<p>\\n\\nKey trial parameters  \n• Design: Randomized, observer-blinded, multi-center study.  \n• Population: 420 older adults aged 60-85 years.  \n• Intervention arms: SCB-1022, SCB-1033, and placebo.  \n• Objectives: Assessment of safety, reactogenicity, and immunogenicity.  \n• Technology platform: Prefusion-stabilized F (PreF)-Trimer antigens leveraging Clover’s Trimer-Tag platform.  \n• Timeline: Initial read-outs are targeted for the third quarter of 2026.</p>\n<p>\\n\\nThe Board advises shareholders and prospective investors to exercise caution when dealing in Clover’s shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02197","symbol_name":"三叶草生物-B","start_time":0,"source_url":"","article_id":"1175306947","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175306947","pubTimestamp":1774823189,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Clover Biopharmaceuticals (Clover) has concluded participant enrollment for its Australian Phase 2 clinical study investigating two protein-based respiratory combination vaccine candidates—SCB-1022...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02197":"三叶草生物-B"},"translate_title":"Clover在澳大利亚RSV-hMPV±PIV3候选疫苗2期试验中完成420名参与者的入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02197":1},"content_text":"Clover Biopharmaceuticals (Clover) has concluded participant enrollment for its Australian Phase 2 clinical study investigating two protein-based respiratory combination vaccine candidates—SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3).\n\\n\\nKey trial parameters  \n• Design: Randomized, observer-blinded, multi-center study.  \n• Population: 420 older adults aged 60-85 years.  \n• Intervention arms: SCB-1022, SCB-1033, and placebo.  \n• Objectives: Assessment of safety, reactogenicity, and immunogenicity.  \n• Technology platform: Prefusion-stabilized F (PreF)-Trimer antigens leveraging Clover’s Trimer-Tag platform.  \n• Timeline: Initial read-outs are targeted for the third quarter of 2026.\n\\n\\nThe Board advises shareholders and prospective investors to exercise caution when dealing in Clover’s shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175306947","isCrawlerRequest":true}